Literature DB >> 6332288

1-Methyl-4-phenylpyridinium ion (MPP+): identification of a metabolite of MPTP, a toxin selective to the substantia nigra.

J W Langston, I Irwin, E B Langston, L S Forno.   

Abstract

MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) is a newly described neurotoxin which selectively destroys cells in the substantia nigra when administered systemically to primates. Because the substance creates a condition in humans which is virtually indistinguishable from Parkinson's disease, interest has focused on its mechanism of action. We now report that MPTP appears to be rapidly metabolized after systemic administration in toxic amounts, and identify 1-methyl-4-phenylpyridinium ion (MPP+) as a probable major metabolite.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6332288     DOI: 10.1016/0304-3940(84)90293-3

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  78 in total

Review 1.  Transplantation into the human brain: present status and future possibilities.

Authors:  O Lindvall
Journal:  J Neurol Neurosurg Psychiatry       Date:  1989-06       Impact factor: 10.154

2.  P-Glycoprotein Transport of Neurotoxic Pesticides.

Authors:  Sarah E Lacher; Kasse Skagen; Joachim Veit; Rachel Dalton; Erica L Woodahl
Journal:  J Pharmacol Exp Ther       Date:  2015-08-13       Impact factor: 4.030

3.  Occurrence and distribution of salsolinol-like compound, 1-acetyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline (ADTIQ) in parkinsonian brains.

Authors:  Yulin Deng; Yongqian Zhang; Yujuan Li; Shengyuan Xiao; Dewei Song; Hong Qing; Qin Li; Ali H Rajput
Journal:  J Neural Transm (Vienna)       Date:  2011-11-08       Impact factor: 3.575

4.  Large animal models are critical for rationally advancing regenerative therapies.

Authors:  Dustin R Wakeman; Andrew M Crain; Evan Y Snyder
Journal:  Regen Med       Date:  2006-07       Impact factor: 3.806

5.  Cytoplasmic Pink1 activity protects neurons from dopaminergic neurotoxin MPTP.

Authors:  M Emdadul Haque; Kelly J Thomas; Cheryl D'Souza; Steve Callaghan; Tohru Kitada; Ruth S Slack; Paul Fraser; Mark R Cookson; Anurag Tandon; David S Park
Journal:  Proc Natl Acad Sci U S A       Date:  2008-01-24       Impact factor: 11.205

6.  Oxidative polymorphism of debrisoquine in Parkinson's disease.

Authors:  J Benitez; J M Ladero; F J Jimenez-Jimenez; C Martinez; A M Puerto; M J Valdivielso; A Llerena; J Cobaleda; J J Muñoz
Journal:  J Neurol Neurosurg Psychiatry       Date:  1990-04       Impact factor: 10.154

7.  Evidence for hydroxyl radical scavenging action of nitric oxide donors in the protection against 1-methyl-4-phenylpyridinium-induced neurotoxicity in rats.

Authors:  Rebecca Banerjee; Karuppagounder S Saravanan; Bobby Thomas; Kizhake M Sindhu; Kochupurackal P Mohanakumar
Journal:  Neurochem Res       Date:  2007-09-01       Impact factor: 3.996

Review 8.  Oxidative stress-induced signaling pathways implicated in the pathogenesis of Parkinson's disease.

Authors:  Georgia S Gaki; Athanasios G Papavassiliou
Journal:  Neuromolecular Med       Date:  2014-02-13       Impact factor: 3.843

9.  Neurobehavioral protection by single dose l-deprenyl against MPTP-induced parkinsonism in common marmosets.

Authors:  Kiyoshi Ando; Jun Maeda; Motoki Inaji; Takashi Okauchi; Shigeru Obayashi; Makoto Higuchi; Tetsuya Suhara; Yoshikuni Tanioka
Journal:  Psychopharmacology (Berl)       Date:  2007-09-19       Impact factor: 4.530

10.  Acetylcholinesterase inhibition by 1-methyl-4-phenylpyridinium ion, a bioactivated metabolite of MPTP.

Authors:  L Y Zang; H P Misra
Journal:  Mol Cell Biochem       Date:  1993-09-22       Impact factor: 3.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.